# | Author | Country | Health condition | Intervention | Study Population size | Study population age range |
---|---|---|---|---|---|---|
1 | Achonduh et al. (2012) [26] | Cameroon | Malaria | Dietary supplements (vitamin A, zinc) and antimalarials (artesunate-amodiaquine) | 100 | 6–24 months |
2 | Adegbehingbe et al. (2010) [27] | Nigeria | Clubfoot | Surgical methods (Ponseti method and extensive soft tissue surgery) | 105 | 0–adult |
3 | Afolabi et al. (2013) [28] | The Gambia | HIV | Vaccine | 48 | 0–9 months |
4 | Aluka et al. (2013) [29] | Nigeria | Fever | Coldwater sponging, oral paracetamol | 88 | 12–120 months |
5 | Amadi et al. (2002) [30] | Zambia | Diarrhoea and malnutrition (cryptosporidiosis) | Antiparasitic (nitazoxanide) | 96 | 1–7 years |
6 | Arimond et al. (2017) [31] | Ghana, Malawi, Burkina Faso | Undernutrition | Dietary supplements (lipid-based) | 2622, 1318, 1093, 625 | 0–18 months |
7 | Armah et al. (2010) [32] | Ghana, Kenya, Mali | Gastroenteritis (Rotavirus) | Vaccine | 5468 | 4–12 weeks |
8 | Armah et al. (2013) [33] | Ghana | Gastroenteritis (Rotavirus) | Vaccine | 998 | 0–29 days |
9 | Christofides et al. (2006) [34] | Ghana | Anaemia (Iron deficiency) | Dietary supplement (iron) | 133 | 6–18 months |
10 | Corbett et al. (2010) [35] | Malawi | HIV | Antiretrovirals (lamivudine, stavudine, nevirapine) | 18 | 1–13 years |
11 | Egere et al. (2012) [36] | The Gambia | Pneumonia (Streptococcus pneumoniae) | Vaccine | 328 | 2–30 months |
12 | Gilliams et al. (2014) [37] | Malawi | Malaria | Antimalarials (chloroquine-azithromycin) | 320 | 20–46 months |
13 | Goodhew et al. (2014) [38] | Tanzania | Trachoma | Mass drug administration (azithromycin) | 264 | 1–6 years |
14 | Hassall et al. (2015) [39] | Kenya | Malaria | Umbilical cord red blood cell transfusion | 55 | 0–6 years |
15 | Hess et al. (2015) [40] | Burkina Faso | Undernutrition (Growth stunting) | Dietary supplements (lipid-based) | 3220 | 9 months |
16 | Hesseling et al. (2005) [41] | Malawi | Burkitt Lymphoma | Chemotherapy (vincristine, methotrexate, leucovorin, cyclophosphamide, prednisone) | 60 | 3–16 years |
17 | Hussey et al. (1990) [42] | South Africa | Measles | Dietary supplement (vitamin A) | 189 | 0–13 years |
18 | Isanaka (2017) [43] | Niger | Gastroenteritis (Rotavirus) | Vaccine | 3508 | 6–14 weeks |
19 | Kone et al. (2010) [44] | Mali | Malaria (Glucose-6-phosphate dehydrogenase deficiency) | Antimalarials (artemether-lumefantrine, artesunate-mefloquine) | 315 | > 1 year |
20 | Koram et al. (2005) [45] | Ghana | Malaria | Antimalarials (amodiaquine-artesunate, artemether-lumefantrine, sulfadoxine-pyrimethamine, chloroquine) | 168 | 6–59 months |
21 | Madhi et al. (2011) [46] | South Africa | Childhood diseases (Hepatitis B, diphtheria, tetanus, pertussis, polio, Haemophilus influaenzae) | Vaccines | 715 | 0–3 days |
22 | Madhi et al. (2012) [47] | South Africa, Malawi | Gastroenteritis (Rotavirus) | Vaccine | 3168 | 6–16 weeks |
23 | Maka et al. (2015) [48] | Cameroon | Malaria | Antimalarials (artesunate, quinine) | 238 | 3 months–15 years |
24 | Mangani et al. (2015) [49] | Malawi | Undernutrition (Growth stunting) | Dietary supplements (lipid-based, corn-soy blend) | 840 | 5.5–6.5 months |
25 | Meremikwu et al. (2006) [50] | Nigeria | Malaria | Antimalarials (artemether-lumefantrine, artesunate-amodiaquine) | 119 | 6–59 months |
26 | Meremikwu et al. (2016) [51] | Nigeria | Malaria | Antimalarials (artesunate-amodiaquine, dihydroartemisinin-piperaquine, artemether-lumefantrine) | 493 | 6–59 months |
27 | Michael et al. (2010) [52] | Nigeria | Malaria | Antimalarials (artemether-lumefantrine, artesunate-amodiaquine) | 193 | 12–132 months |
28 | Ngasala et al. (2011) [53] | Tanzania | Malaria | Antimalarials (artemether-lumefantrine) | 300 | 3–59 months |
29 | Nji et al. (2015) [54] | Cameroon | Malaria | Antimalarials (dihydroartemisin-piperaquine, artesunate-amodiaquine vs artemether-lumefantrine) | 720 | 6 months–10 years |
30 | Nwanyanwu et al. (1996) [55] | Malawi | Malaria | Antimalarials (sulphadoxine-pyrimethamine) | 159 | 0–5 years |
31 | Phuka et al. (2008) [56] | Malawi | Undernutrition (Growth stunting) | Dietary supplements (fortified spread, micronutrient-fortified maize-soy flour) | 182 | 6–18 months |
32 | Rahimy et al. (1999) [57] | Benin | Fever (in Sickle Cell Disease) | Antibiotics (outpatient management) | 61 | 0–12 years |
33 | Robertson et al. (2011) [58] | Uganda | Perinatal asphyxial encephalopathy | Therapeutic hypothermia | 36 | 3 h |
34 | Roca et al. (2011) [59] | The Gambia | Pneumococcal disease | Vaccine | 5441 | 0–adult |
35 | Sazawal et al. (2007) [60] | Zanzibar | Undernutrition (Mortality) | Dietary supplement (zinc) | 42,546 | 1–36 months |
36 | Schellenberg et al. (2001) [61] | Tanzania | Malaria and anaemia | Antimalarials (sulphadoxine-pyrimethamine) alongside routine vaccinations | 701 | 0–1 year |
37 | Singana et al. (2016) [62] | Republic of Congo | Malaria | Antimalarials (artesunate-amodiaquine, artemether-lumefantrine) | 198 | < 12 years |
38 | Sissoko et al. (2016) [63] | Guinea | Ebola | Antiviral (favipiravir) | 111 | > 1 year |
39 | Sow et al. (2012) [64] | Mali | Gastroenteritis (Rotavirus) | Vaccine | 1960 | 48 days (median age) |
40 | Te Water Naude et al. (2000) [65] | South Africa | Tuberculosis | Chemotherapy (isoniazid, rifampin, pyrazinamide) | 206 | 0–14 years |
41 | The Zinc Against Plasmodium Study Group (2002) [66] | Ecuador, Ghana, Tanzania, Uganda, Zambia | Malaria | Antimalarial and dietary supplement (chloroquine and zinc) | 1087 | 6–60 months |
42 | Urban et al. (2008) [67] | South Africa | Nutrition (Infant growth) | Dietary supplements (biologically acidified milk, probiotics) | 85 | 0–1 week |
43 | Waggie et al. (2011) [68] | South Africa | Polio | Vaccine | 800 | 0–30 days |
44 | Yohannan et al. (2013) [69] | Tanzania | Trachoma | Mass drug administration (azithromycin, tetracycline) | 2261 | 0–5 years |